{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:16:19Z","timestamp":1794050179847,"version":"4.8.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82272347"],"award-info":[{"award-number":["No.82272347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Capital Health Research and Development of Special Fund","award":["No.2022-1G-2161"],"award-info":[{"award-number":["No.2022-1G-2161"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02443-4","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T22:24:11Z","timestamp":1744323851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Host-directed therapy for tuberculosis"],"prefix":"10.1186","volume":"30","author":[{"given":"Na","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaogang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2443_CR1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023."},{"key":"2443_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.665785","volume":"12","author":"SC Mitini-Nkhoma","year":"2021","unstructured":"Mitini-Nkhoma SC, Chimbayo ET, Mzinza DT, Mhango DV, Chirambo AP, Mandalasi C, Lakudzala AE, Tembo DL, Jambo KC, Mwandumba HC. Something old, something new: ion channel blockers as potential anti-tuberculosis agents. Front Immunol. 2021;12: 665785.","journal-title":"Front Immunol"},{"key":"2443_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/infdis\/jiy712","volume":"219","author":"DJ Frank","year":"2019","unstructured":"Frank DJ, Horne DJ, Dutta NK, Shaku MT, Madensein R, Hawn TR, Steyn AJC, Karakousis PC, Kana BD, Meintjes G, et al. Remembering the host in tuberculosis drug development. J Infect Dis. 2019;219:1518\u201324.","journal-title":"J Infect Dis"},{"key":"2443_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021196","volume":"5","author":"DM Tobin","year":"2015","unstructured":"Tobin DM. Host-directed therapies for tuberculosis. Cold Spring Harb Perspect Med. 2015;5: a021196.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2443_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17:35\u201356.","journal-title":"Nat Rev Drug Discov"},{"key":"2443_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.addr.2016.04.024","volume":"102","author":"G O'Connor","year":"2016","unstructured":"O\u2019Connor G, Gleeson LE, Fagan-Murphy A, Cryan SA, O\u2019Sullivan MP, Keane J. Sharpening nature\u2019s tools for efficient tuberculosis control: a review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv Drug Deliv Rev. 2016;102:33\u201354.","journal-title":"Adv Drug Deliv Rev"},{"key":"2443_CR7","doi-asserted-by":"publisher","first-page":"1802003","DOI":"10.1183\/13993003.02003-2018","volume":"53","author":"DA Jolliffe","year":"2019","unstructured":"Jolliffe DA, Ganmaa D, Wejse C, Raqib R, Haq MA, Salahuddin N, Daley PK, Ralph AP, Ziegler TR, Martineau AR. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data. Eur Respir J. 2019;53:1802003.","journal-title":"Eur Respir J"},{"key":"2443_CR8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"SP Parihar","year":"2014","unstructured":"Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis. 2014;209:754\u201363.","journal-title":"J Infect Dis"},{"key":"2443_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4161\/auto.3711","volume":"3","author":"W Martinet","year":"2007","unstructured":"Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy. 2007;3:241\u20134.","journal-title":"Autophagy"},{"key":"2443_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003946","volume":"10","author":"SA Stanley","year":"2014","unstructured":"Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 2014;10: e1003946.","journal-title":"PLoS Pathog"},{"key":"2443_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1021\/acsinfecdis.7b00046","volume":"3","author":"KM Sogi","year":"2017","unstructured":"Sogi KM, Lien KA, Johnson JR, Krogan NJ, Stanley SA. The tyrosine kinase inhibitor gefitinib restricts Mycobacterium tuberculosis growth through increased lysosomal biogenesis and modulation of cytokine signaling. ACS Infect Dis. 2017;3:564\u201374.","journal-title":"ACS Infect Dis"},{"key":"2443_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1165\/rcmb.2015-0383OC","volume":"55","author":"E Ju\u00e1rez","year":"2016","unstructured":"Ju\u00e1rez E, Carranza C, S\u00e1nchez G, Gonz\u00e1lez M, Ch\u00e1vez J, Sarabia C, Torres M, Sada E. Loperamide restricts intracellular growth of Mycobacterium tuberculosis in lung macrophages. Am J Respir Cell Mol Biol. 2016;55:837\u201347.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2443_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.09.013","volume":"65","author":"E Ju\u00e1rez","year":"2018","unstructured":"Ju\u00e1rez E, Ruiz A, Cortez O, Sada E, Torres M. Antimicrobial and immunomodulatory activity induced by loperamide in mycobacterial infections. Int Immunopharmacol. 2018;65:29\u201336.","journal-title":"Int Immunopharmacol"},{"key":"2443_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ebiom.2015.07.014","volume":"2","author":"M Maiga","year":"2015","unstructured":"Maiga M, Ahidjo BA, Maiga MC, Cheung L, Pelly S, Lun S, Bougoudogo F, Bishai WR. Efficacy of adjunctive tofacitinib therapy in mouse models of tuberculosis. EBioMedicine. 2015;2:868\u201373.","journal-title":"EBioMedicine"},{"key":"2443_CR15","first-page":"126","volume":"20","author":"M Sheikhpour","year":"2021","unstructured":"Sheikhpour M, Shokrgozar MA, Biglari A, Pornour M, Abdolrahimi F, Poorazar Dizaji S, Khanipour S, Masoumi M, Ebrahimzadeh N, Abolfathi H. Gene expression and in vitro pharmacogenetic studies of dopamine and serotonin gene receptors in tuberculosis. Tanaffos. 2021;20:126\u201333.","journal-title":"Tanaffos"},{"key":"2443_CR16","doi-asserted-by":"publisher","first-page":"15251","DOI":"10.1038\/s41598-019-51803-8","volume":"9","author":"S Panda","year":"2019","unstructured":"Panda S, Tiwari A, Luthra K, Sharma SK, Singh A. Association of Fok1 VDR polymorphism with Vitamin D and its associated molecules in pulmonary tuberculosis patients and their household contacts. Sci Rep. 2019;9:15251.","journal-title":"Sci Rep"},{"key":"2443_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.intimp.2018.12.015","volume":"67","author":"X Zhu","year":"2019","unstructured":"Zhu X, Zhu Y, Li C, Yu J, Ren D, Qiu S, Nie Y, Yu X, Xu X, Zhu W. 1,25-Dihydroxyvitamin D regulates macrophage polarization and ameliorates experimental inflammatory bowel disease by suppressing miR-125b. Int Immunopharmacol. 2019;67:106\u201318.","journal-title":"Int Immunopharmacol"},{"key":"2443_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4049\/jimmunol.136.3.1049","volume":"136","author":"MS Cohen","year":"1986","unstructured":"Cohen MS, Mesler DE, Snipes RG, Gray TK. 1,25-Dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes. J Immunol. 1986;136:1049\u201353.","journal-title":"J Immunol"},{"key":"2443_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002691","volume":"8","author":"KK Lam","year":"2012","unstructured":"Lam KK, Zheng X, Forestieri R, Balgi AD, Nodwell M, Vollett S, Anderson HJ, Andersen RJ, Av-Gay Y, Roberge M. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog. 2012;8: e1002691.","journal-title":"PLoS Pathog"},{"key":"2443_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.isci.2019.11.001","volume":"22","author":"S Ranjbar","year":"2019","unstructured":"Ranjbar S, Haridas V, Nambu A, Jasenosky LD, Sadhukhan S, Ebert TS, Hornung V, Cassell GH, Falvo JV, Goldfeld AE. Cytoplasmic RNA sensor pathways and nitazoxanide broadly inhibit intracellular Mycobacterium tuberculosis growth. iScience. 2019;22:299\u2013313.","journal-title":"iScience"},{"key":"2443_CR21","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1021\/acs.molpharmaceut.6b00459","volume":"13","author":"A Gupta","year":"2016","unstructured":"Gupta A, Meena J, Sharma D, Gupta P, Gupta UD, Kumar S, Sharma S, Panda AK, Misra A. Inhalable particles for \u201cpincer therapeutics\u201d targeting nitazoxanide as bactericidal and host-directed agent to macrophages in a mouse model of tuberculosis. Mol Pharm. 2016;13:3247\u201355.","journal-title":"Mol Pharm"},{"key":"2443_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cpt.3108","volume":"115","author":"C Padmapriyadarsini","year":"2024","unstructured":"Padmapriyadarsini C, Szumowski JD, Akbar N, Shanmugasundaram P, Jain A, Bathragiri M, Pattnaik M, Turuk J, Karunaianantham R, Balakrishnan S, et al. A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis. Clin Pharmacol Ther. 2024;115:324\u201332.","journal-title":"Clin Pharmacol Ther"},{"key":"2443_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.fsi.2019.11.051","volume":"96","author":"Y Kan","year":"2020","unstructured":"Kan Y, Meng L, Xie L, Liu L, Dong W, Feng J, Yan Y, Zhao C, Peng G, Wang D, et al. Temporal modulation of host aerobic glycolysis determines the outcome of Mycobacterium marinum infection. Fish Shellfish Immunol. 2020;96:78\u201385.","journal-title":"Fish Shellfish Immunol"},{"key":"2443_CR24","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.3389\/fimmu.2019.03042","volume":"10","author":"I Palucci","year":"2019","unstructured":"Palucci I, Maulucci G, De Maio F, Sali M, Romagnoli A, Petrone L, Fimia GM, Sanguinetti M, Goletti D, De Spirito M, et al. Inhibition of transglutaminase 2 as a potential host-directed therapy against Mycobacterium tuberculosis. Front Immunol. 2019;10:3042.","journal-title":"Front Immunol"},{"key":"2443_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252097","volume":"17","author":"RS Wallis","year":"2022","unstructured":"Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Sebe M, Edward VA, Rassool M, Ahmed K, Fielding K, et al. Lung and blood early biomarkers for host-directed tuberculosis therapies: secondary outcome measures from a randomized controlled trial. PLoS ONE. 2022;17: e0252097.","journal-title":"PLoS ONE"},{"key":"2443_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.657775","volume":"11","author":"K To","year":"2021","unstructured":"To K, Cao R, Yegiazaryan A, Owens J, Nguyen T, Sasaninia K, Vaughn C, Singh M, Truong E, Medina A, et al. Effects of oral liposomal glutathione in altering the immune responses against Mycobacterium tuberculosis and the Mycobacterium bovis BCG strain in individuals with type 2 diabetes. Front Cell Infect Microbiol. 2021;11: 657775.","journal-title":"Front Cell Infect Microbiol"},{"key":"2443_CR27","first-page":"3767915","volume":"2020","author":"SC Mitini-Nkhoma","year":"2020","unstructured":"Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL. Ion transport modulators as antimycobacterial agents. Tuberc Res Treat. 2020;2020:3767915.","journal-title":"Tuberc Res Treat"},{"key":"2443_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002231","volume":"21","author":"VK Biswas","year":"2023","unstructured":"Biswas VK, Sen K, Ahad A, Ghosh A, Verma S, Pati R, Prusty S, Nayak SP, Podder S, Kumar D, et al. NCoR1 controls Mycobacterium tuberculosis growth in myeloid cells by regulating the AMPK\u2013mTOR\u2013TFEB axis. PLoS Biol. 2023;21: e3002231.","journal-title":"PLoS Biol"},{"key":"2443_CR29","first-page":"e00036","volume":"6","author":"A Madhavan","year":"2021","unstructured":"Madhavan A, Arun KB, Pushparajan AR, Balaji M, Kumar RA. Transcription repressor protein ZBTB25 associates with HDAC1-Sin3a complex in Mycobacterium tuberculosis-infected macrophages, and its inhibition clears pathogen by autophagy. J mSphere. 2021;6:e00036-e121.","journal-title":"J mSphere"},{"key":"2443_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251067","volume":"16","author":"S Kwon","year":"2021","unstructured":"Kwon S, Chun HL, Ha HJ, Lee SY, Park HH. Heterogeneous multimeric structure of isocitrate lyase in complex with succinate and itaconate provides novel insights into its inhibitory mechanism. PLoS ONE. 2021;16: e0251067.","journal-title":"PLoS ONE"},{"key":"2443_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2020.00152","volume":"11","author":"AS Wentzel","year":"2020","unstructured":"Wentzel AS, Janssen JJE, de Boer VCJ, van Veen WG, Forlenza M, Wiegertjes GF. Fish macrophages show distinct metabolic signatures upon polarization. Front Immunol. 2020;11:152.","journal-title":"Front Immunol"},{"key":"2443_CR32","doi-asserted-by":"publisher","first-page":"e0212121","DOI":"10.1128\/mBio.02121-21","volume":"12","author":"A Gidon","year":"2021","unstructured":"Gidon A, Louet C, R\u00f8st LM, Bruheim P, Flo TH. The tumor necrosis factor alpha and interleukin 6 auto-paracrine signaling loop controls Mycobacterium avium infection via induction of IRF1\/IRG1 in human primary macrophages. MBio. 2021;12:e0212121.","journal-title":"MBio"},{"key":"2443_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030749","volume":"7","author":"M Maiga","year":"2012","unstructured":"Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE. 2012;7: e30749.","journal-title":"PLoS ONE"},{"key":"2443_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/infdis\/jit187","volume":"208","author":"M Maiga","year":"2013","unstructured":"Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, Murphy R, Bishai WR. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis. 2013;208:512\u20139.","journal-title":"J Infect Dis"},{"key":"2443_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ebiom.2016.01.015","volume":"4","author":"S Subbian","year":"2016","unstructured":"Subbian S, Tsenova L, Holloway J, Peixoto B, O\u2019Brien P, Dartois V, Khetani V, Zeldis JB, Kaplan G. Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model. EBioMedicine. 2016;4:104\u201314.","journal-title":"EBioMedicine"},{"key":"2443_CR36","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1038\/s41467-023-43304-0","volume":"14","author":"S Parveen","year":"2023","unstructured":"Parveen S, Shen J, Lun S, Zhao L, Koleske B, Leone RD, Rais R, Powell JD, Murphy JR, Slusher BS, et al. Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis. Nat Commun. 2023;14:7427.","journal-title":"Nat Commun"},{"key":"2443_CR37","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1073\/pnas.1424563112","volume":"112","author":"M Datta","year":"2015","unstructured":"Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, Weiner DM, Schimel D, England K, Martin JD, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A. 2015;112:1827\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2443_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","volume":"29","author":"Y Wang","year":"2019","unstructured":"Wang Y, An H, Liu T, Qin C, Sesaki H, Guo S, Radovick S, Hussain M, Maheshwari A, Wondisford FE, et al. Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep. 2019;29:1511-1523.e1515.","journal-title":"Cell Rep"},{"key":"2443_CR39","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1016\/j.apsb.2021.05.027","volume":"11","author":"X Zheng","year":"2021","unstructured":"Zheng X, Li W, Xu H, Liu J, Ren L, Yang Y, Li S, Wang J, Ji T, Du G. Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K\/AKT\/mTOR and AMPK\/mTOR pathway. Acta Pharm Sin B. 2021;11:3465\u201380.","journal-title":"Acta Pharm Sin B"},{"key":"2443_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132\u201341.","journal-title":"Nat Cell Biol"},{"key":"2443_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.33478","volume":"7","author":"NTH Mai","year":"2018","unstructured":"Mai NTH, Dobbs N, Phu NH, Colas RA, Thao LTP, Thuong NTT, Nghia HDT, Hanh NHH, Hang NT, Heemskerk AD, et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife. 2018;7: e33478.","journal-title":"Elife"},{"key":"2443_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jac\/dkl486","volume":"59","author":"ST Byrne","year":"2007","unstructured":"Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother. 2007;59:313\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"2443_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jit152","volume":"208","author":"C Vilaplana","year":"2013","unstructured":"Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis. 2013;208:199\u2013202.","journal-title":"J Infect Dis"},{"key":"2443_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/s12879-016-1938-8","volume":"16","author":"K Tonby","year":"2016","unstructured":"Tonby K, Wergeland I, Lieske NV, Kvale D, Tasken K, Dyrhol-Riise AM. The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection. BMC Infect Dis. 2016;16:599.","journal-title":"BMC Infect Dis"},{"key":"2443_CR45","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.3389\/fmicb.2017.02370","volume":"8","author":"VR Parasa","year":"2017","unstructured":"Parasa VR, Muvva JR, Rose JF, Braian C, Brighenti S, Lerm M. Inhibition of tissue matrix metalloproteinases interferes with Mycobacterium tuberculosis-induced granuloma formation and reduces bacterial load in a human lung tissue model. Front Microbiol. 2017;8:2370.","journal-title":"Front Microbiol"},{"key":"2443_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004917","volume":"11","author":"CW Ong","year":"2015","unstructured":"Ong CW, Elkington PT, Brilha S, Ugarte-Gil C, Tome-Esteban MT, Tezera LB, Pabisiak PJ, Moores RC, Sathyamoorthy T, Patel V, et al. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog. 2015;11: e1004917.","journal-title":"PLoS Pathog"},{"key":"2443_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.abb.2019.04.006","volume":"667","author":"H Yang","year":"2019","unstructured":"Yang H, Hu J, Chen YJ, Ge B. Role of Sirt1 in innate immune mechanisms against Mycobacterium tuberculosis via the inhibition of TAK1 activation. Arch Biochem Biophys. 2019;667:49\u201358.","journal-title":"Arch Biochem Biophys"},{"key":"2443_CR48","doi-asserted-by":"publisher","first-page":"108612","DOI":"10.1016\/j.abb.2020.108612","volume":"694","author":"H Yang","year":"2020","unstructured":"Yang H, Chen J, Chen Y, Jiang Y, Ge B, Hong L. Sirtuin inhibits M. tuberculosis -induced apoptosis in macrophage through glycogen synthase kinase-3\u03b2. Arch Biochem Biophys. 2020;694:108612.","journal-title":"Arch Biochem Biophys"},{"key":"2443_CR49","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1093\/cid\/ciaa1826","volume":"72","author":"R van Toorn","year":"2021","unstructured":"van Toorn R, Solomons RS, Seddon JA, Schoeman JF. Thalidomide use for complicated central nervous system tuberculosis in children: insights from an observational cohort. Clin Infect Dis. 2021;72:e136\u201345.","journal-title":"Clin Infect Dis"},{"key":"2443_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659943","volume":"12","author":"FEA Hayford","year":"2021","unstructured":"Hayford FEA, Ozturk M, Dolman RC, Blaauw R, Nienaber A, Loots DT, Brombacher F, Smuts CM, Parihar SP, Malan L. Longer-term omega-3 LCPUFA more effective adjunct therapy for tuberculosis than ibuprofen in a C3HeB\/FeJ tuberculosis mouse model. Front Immunol. 2021;12: 659943.","journal-title":"Front Immunol"},{"key":"2443_CR51","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3390\/nu12092897","volume":"12","author":"A Nienaber","year":"2020","unstructured":"Nienaber A, Baumgartner J, Dolman RC, Ozturk M, Zandberg L, Hayford FEA, Brombacher F, Blaauw R, Parihar SP, Smuts CM, et al. Omega-3 fatty acid and iron supplementation alone, but not in combination, lower inflammation and anemia of infection in Mycobacterium tuberculosis-infected mice. Nutrients. 2020;12:2897.","journal-title":"Nutrients"},{"key":"2443_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1017\/S0007114521001124","volume":"127","author":"A Nienaber","year":"2022","unstructured":"Nienaber A, Ozturk M, Dolman R, Blaauw R, Zandberg LL, van Rensburg S, Britz M, Hayford FEA, Brombacher F, Loots DT, et al. n-3 long-chain PUFA promote antibacterial and inflammation-resolving effects in Mycobacterium tuberculosis-infected C3HeB\/FeJ mice, dependent on fatty acid status. Br J Nutr. 2022;127:384\u201397.","journal-title":"Br J Nutr"},{"key":"2443_CR53","doi-asserted-by":"publisher","first-page":"10692","DOI":"10.1074\/jbc.M113.455915","volume":"288","author":"V Chandra","year":"2013","unstructured":"Chandra V, Mahajan S, Saini A, Dkhar HK, Nanduri R, Raj EB, Kumar A, Gupta P. Human IL10 gene repression by Rev-erb\u03b1 ameliorates Mycobacterium tuberculosis clearance. J Biol Chem. 2013;288:10692\u2013702.","journal-title":"J Biol Chem"},{"key":"2443_CR54","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.4049\/jimmunol.1601920","volume":"198","author":"YS Kim","year":"2017","unstructured":"Kim YS, Lee HM, Kim JK, Yang CS, Kim TS, Jung M, Jin HS, Kim S, Jang J, Oh GT, et al. PPAR-\u03b1 activation mediates innate host defense through induction of TFEB and lipid catabolism. J Immunol. 2017;198:3283\u201395.","journal-title":"J Immunol"},{"key":"2443_CR55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/15548627.2017.1339001","volume":"14","author":"SY Kim","year":"2018","unstructured":"Kim SY, Yang CS, Lee HM, Kim JK, Kim YS, Kim YR, Kim JS, Kim TS, Yuk JM, Dufour CR, et al. ESRRA (estrogen-related receptor \u03b1) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense. Autophagy. 2018;14:152\u201368.","journal-title":"Autophagy"},{"key":"2443_CR56","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1038\/s41564-019-0578-3","volume":"4","author":"DX Ji","year":"2019","unstructured":"Ji DX, Yamashiro LH, Chen KJ, Mukaida N, Kramnik I, Darwin KH, Vance RE. Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat Microbiol. 2019;4:2128\u201335.","journal-title":"Nat Microbiol"},{"key":"2443_CR57","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41556-018-0092-5","volume":"20","author":"N Mizushima","year":"2018","unstructured":"Mizushima N. A brief history of autophagy from cell biology to physiology and disease. Nat Cell Biol. 2018;20:521\u20137.","journal-title":"Nat Cell Biol"},{"key":"2443_CR58","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1194\/jlr.RA120000895","volume":"61","author":"N Bruiners","year":"2020","unstructured":"Bruiners N, Dutta NK, Guerrini V, Salamon H, Yamaguchi KD, Karakousis PC, Gennaro ML. The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis. J Lipid Res. 2020;61:1617\u201328.","journal-title":"J Lipid Res"},{"key":"2443_CR59","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3389\/fmicb.2019.02097","volume":"10","author":"PDC Guerra-De-Blas","year":"2019","unstructured":"Guerra-De-Blas PDC, Bobadilla-Del-Valle M, Sada-Ovalle I, Estrada-Garc\u00eda I, Torres-Gonz\u00e1lez P, L\u00f3pez-Saavedra A, Guzm\u00e1n-Beltr\u00e1n S, Ponce-de-Le\u00f3n A, Sifuentes-Osornio J. Simvastatin enhances the immune response against Mycobacterium tuberculosis. Front Microbiol. 2019;10:2097.","journal-title":"Front Microbiol"},{"key":"2443_CR60","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/infdis\/jiz517","volume":"221","author":"NK Dutta","year":"2020","unstructured":"Dutta NK, Bruiners N, Zimmerman MD, Tan S, Dartois V, Gennaro ML, Karakousis PC. Adjunctive Host-directed therapy with statins improves tuberculosis-related outcomes in mice. J Infect Dis. 2020;221:1079\u201387.","journal-title":"J Infect Dis"},{"key":"2443_CR61","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5588\/ijtld.22.0548","volume":"27","author":"OO Adewole","year":"2023","unstructured":"Adewole OO, Omotoso BA, Ogunsina M, Aminu A, Odeyemi AO, Awopeju OF, Ayoola O, Adedeji T, Sogaolu OM, Adewole TO, et al. Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial. Int J Tuberc Lung Dis. 2023;27:226\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2443_CR62","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1473-3099(23)00067-1","volume":"23","author":"GB Cross","year":"2023","unstructured":"Cross GB, Sari IP, Kityo C, Lu Q, Pokharkar Y, Moorakonda RB, Thi HN, Do Q, Dalay VB, Gutierrez E, et al. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial. Lancet Infect Dis. 2023;23:847\u201355.","journal-title":"Lancet Infect Dis"},{"key":"2443_CR63","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1200\/JCO.2008.16.2347","volume":"26","author":"A Jimeno","year":"2008","unstructured":"Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008;26:4172\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2443_CR64","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361\u201371.","journal-title":"Cell"},{"key":"2443_CR65","doi-asserted-by":"publisher","first-page":"dmm049018","DOI":"10.1242\/dmm.049018","volume":"14","author":"K Bhatt","year":"2021","unstructured":"Bhatt K, Bhagavathula M, Verma S, Timmins GS, Deretic VP, Ellner JJ, Salgame P. Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection. Dis Model Mech. 2021;14:dmm049018.","journal-title":"Dis Model Mech"},{"key":"2443_CR66","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/jcm9072043","volume":"9","author":"D Ashley","year":"2020","unstructured":"Ashley D, Hernandez J, Cao R, To K, Yegiazaryan A, Abrahem R, Nguyen T, Owens J, Lambros M, Subbian S, et al. Antimycobacterial effects of everolimus in a human granuloma model. J Clin Med. 2020;9:2043.","journal-title":"J Clin Med"},{"key":"2443_CR67","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","volume":"9","author":"RS Wallis","year":"2021","unstructured":"Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021;9:897\u2013908.","journal-title":"Lancet Respir Med"},{"key":"2443_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","volume":"10","author":"RJ Napier","year":"2011","unstructured":"Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe. 2011;10:475\u201385.","journal-title":"Cell Host Microbe"},{"key":"2443_CR69","first-page":"107","volume":"8","author":"MMK Kumar","year":"2018","unstructured":"Kumar MMK, Madhavi K, Mohan T, Nagasree KP, Sangeeta GJ. Novel synthetic analogues of Fluoxetine as potent and selective anti-TB agents. J Appl Pharm Sci. 2018;8:107\u201315.","journal-title":"J Appl Pharm Sci"},{"key":"2443_CR70","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64834","volume":"12","author":"D Shankaran","year":"2023","unstructured":"Shankaran D, Singh A, Dawa S, Arumugam P, Gandotra S, Rao V. The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy. Elife. 2023;12: e64834.","journal-title":"Elife"},{"key":"2443_CR71","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/mmy\/myaa033","volume":"58","author":"DR Boulware","year":"2020","unstructured":"Boulware DR, Nalintya E, Rajasingham R, Kirumira P, Naluyima R, Turya F, Namanda S, Rutakingirwa MK, Skipper CP, Nikweri Y, et al. Adjunctive sertraline for asymptomatic cryptococcal antigenemia: a randomized clinical trial. Med Mycol. 2020;58:1037\u201343.","journal-title":"Med Mycol"},{"key":"2443_CR72","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.4049\/jimmunol.178.11.7190","volume":"178","author":"AR Martineau","year":"2007","unstructured":"Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, Davidson RN, S\u00f8rensen OE, Kampmann B, Griffiths CJ, et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol. 2007;178:7190\u20138.","journal-title":"J Immunol"},{"key":"2443_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jsbmb.2018.09.003","volume":"186","author":"RC Tuckey","year":"2019","unstructured":"Tuckey RC, Cheng CYS, Slominski AT. The serum vitamin D metabolome: what we know and what is still to discover. J Steroid Biochem Mol Biol. 2019;186:4\u201321.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2443_CR74","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655\u201362.","journal-title":"Nature"},{"key":"2443_CR75","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/ijms23031112","volume":"23","author":"M Druszczy\u0144ska","year":"2022","unstructured":"Druszczy\u0144ska M, Godkowicz M, Kulesza J, Wawrocki S, Fol M. Cytokine receptors-regulators of antimycobacterial immune response. Int J Mol Sci. 2022;23:1112.","journal-title":"Int J Mol Sci"},{"key":"2443_CR76","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12879-022-07427-x","volume":"22","author":"Y Wen","year":"2022","unstructured":"Wen Y, Li L, Deng Z. Calcitriol supplementation accelerates the recovery of patients with tuberculosis who have vitamin D deficiency: a randomized, single-blind, controlled clinical trial. BMC Infect Dis. 2022;22:436.","journal-title":"BMC Infect Dis"},{"key":"2443_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272682","volume":"18","author":"S Sinha","year":"2023","unstructured":"Sinha S, Thukral H, Shareef I, Desai D, Singh BK, Das BK, Dhooria S, Sarin R, Singla R, Meena SK, et al. Prevention of relapse in drug sensitive pulmonary tuberculosis patients with and without vitamin D3 supplementation: a double blinded randomized control clinical trial. PLoS ONE. 2023;18: e0272682.","journal-title":"PLoS ONE"},{"key":"2443_CR78","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1039\/C9FO02751C","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Xiong K, Wang Q, Zhao S, Liu Y, Ma A. Adjunctive vitamin A and D during pulmonary tuberculosis treatment: a randomized controlled trial with a 2 \u00d7 2 factorial design. Food Funct. 2020;11:4672\u201381.","journal-title":"Food Funct"},{"key":"2443_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010481","volume":"18","author":"P Koszalka","year":"2022","unstructured":"Koszalka P, Subbarao K, Baz M. Preclinical and clinical developments for combination treatment of influenza. PLoS Pathog. 2022;18: e1010481.","journal-title":"PLoS Pathog"},{"key":"2443_CR80","doi-asserted-by":"publisher","first-page":"e01956","DOI":"10.1128\/AAC.01956-19","volume":"64","author":"KF Walsh","year":"2020","unstructured":"Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Jean Francois D, Zimmerman M, Kaya F, Zhang N, Saito K, et al. Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis. Antimicrob Agents Chemother. 2020;64:e01956-e2019.","journal-title":"Antimicrob Agents Chemother"},{"key":"2443_CR81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40824-023-00342-5","volume":"27","author":"DK Kim","year":"2023","unstructured":"Kim DK, Han D, Bae J, Kim H, Lee S, Kim JS, Jeong YG, Shin J, Park HW. Verapamil-loaded supramolecular hydrogel patch attenuates metabolic dysfunction-associated fatty liver disease via restoration of autophagic clearance of aggregated proteins and inhibition of NLRP3. Biomater Res. 2023;27:4.","journal-title":"Biomater Res"},{"issue":"1","key":"2443_CR82","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/AAC.01462-13","volume":"58","author":"S Gupta","year":"2014","unstructured":"Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(1):574\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2443_CR83","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1128\/AAC.06003-11","volume":"56","author":"M Balganesh","year":"2012","unstructured":"Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother. 2012;56(5):2643\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2443_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","volume":"145","author":"KN Adams","year":"2011","unstructured":"Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011;145(1):39\u201353.","journal-title":"Cell"},{"key":"2443_CR85","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1021\/acs.molpharmaceut.5b00833","volume":"13","author":"T Parumasivam","year":"2016","unstructured":"Parumasivam T, Chan JG, Pang A, Quan DH, Triccas JA, Britton WJ, Chan HK. In vitro evaluation of inhalable verapamil-rifapentine particles for tuberculosis therapy. Mol Pharm. 2016;13:979\u201389.","journal-title":"Mol Pharm"},{"key":"2443_CR86","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1164\/rccm.201304-0650OC","volume":"188","author":"S Gupta","year":"2013","unstructured":"Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med. 2013;188:600\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"2443_CR87","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","volume":"79","author":"GL Lemma","year":"2006","unstructured":"Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79:218\u201330.","journal-title":"Clin Pharmacol Ther"},{"key":"2443_CR88","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20172020","volume":"215","author":"L Huang","year":"2018","unstructured":"Huang L, Nazarova EV, Tan S, Liu Y, Russell DG. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J Exp Med. 2018;215:1135\u201352.","journal-title":"J Exp Med"},{"key":"2443_CR89","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/iub.1251","volume":"66","author":"H Xi","year":"2014","unstructured":"Xi H, Kurtoglu M, Lampidis TJ. The wonders of 2-deoxy-D-glucose. IUBMB Life. 2014;66:110\u201321.","journal-title":"IUBMB Life"},{"key":"2443_CR90","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1172\/JCI27607","volume":"116","author":"M Borrell-Pag\u00e8s","year":"2006","unstructured":"Borrell-Pag\u00e8s M, Canals JM, Cordeli\u00e8res FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006;116:1410\u201324.","journal-title":"J Clin Invest"},{"key":"2443_CR91","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.abb.2003.11.021","volume":"423","author":"T Jaeger","year":"2004","unstructured":"Jaeger T, Budde H, Floh\u00e9 L, Menge U, Singh M, Trujillo M, Radi R. Multiple thioredoxin-mediated routes to detoxify hydroperoxides in Mycobacterium tuberculosis. Arch Biochem Biophys. 2004;423:182\u201391.","journal-title":"Arch Biochem Biophys"},{"key":"2443_CR92","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1146\/annurev.bi.52.070183.003431","volume":"52","author":"A Meister","year":"1983","unstructured":"Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983;52:711\u201360.","journal-title":"Annu Rev Biochem"},{"key":"2443_CR93","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1128\/IAI.73.3.1886-1889.2005","volume":"73","author":"V Venketaraman","year":"2005","unstructured":"Venketaraman V, Dayaram YK, Talaue MT, Connell ND. Glutathione and nitrosoglutathione in macrophage defense against Mycobacterium tuberculosis. Infect Immun. 2005;73:1886\u20139.","journal-title":"Infect Immun"},{"key":"2443_CR94","doi-asserted-by":"publisher","first-page":"e01019","DOI":"10.1128\/AAC.01019-18","volume":"62","author":"SW Choi","year":"2018","unstructured":"Choi SW, Gu Y, Peters RS, Salgame P, Ellner JJ, Timmins GS, Deretic V. Ambroxol induces autophagy and potentiates rifampin antimycobacterial activity. Antimicrob Agents Chemother. 2018;62:e01019-e1118.","journal-title":"Antimicrob Agents Chemother"},{"key":"2443_CR95","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/eurheartj\/ehz667","volume":"41","author":"S Oppi","year":"2020","unstructured":"Oppi S, Nusser-Stein S, Blyszczuk P, Wang X, Jomard A, Marzolla V, Yang K, Velagapudi S, Ward LJ, Yuan XM, et al. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR\u03b3 signature. Eur Heart J. 2020;41:995\u20131005.","journal-title":"Eur Heart J"},{"key":"2443_CR96","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1146\/annurev-immunol-032712-100022","volume":"36","author":"AJ Pag\u00e1n","year":"2018","unstructured":"Pag\u00e1n AJ, Ramakrishnan L. The formation and function of granulomas. Annu Rev Immunol. 2018;36:639\u201365.","journal-title":"Annu Rev Immunol"},{"key":"2443_CR97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/pathogens11010061","volume":"11","author":"MV Palmer","year":"2022","unstructured":"Palmer MV, Kanipe C, Boggiatto PM. The bovine tuberculoid granuloma. Pathogens. 2022;11:61.","journal-title":"Pathogens"},{"key":"2443_CR98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2013.00098","volume":"4","author":"E Guirado","year":"2013","unstructured":"Guirado E, Schlesinger LS. Modeling the Mycobacterium tuberculosis granuloma\u2014the critical battlefield in host immunity and disease. Front Immunol. 2013;4:98.","journal-title":"Front Immunol"},{"key":"2443_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrmicro1538","volume":"5","author":"DG Russell","year":"2007","unstructured":"Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol. 2007;5:39\u201347.","journal-title":"Nat Rev Microbiol"},{"key":"2443_CR100","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm1252","volume":"11","author":"EJ Mu\u00f1oz-El\u00edas","year":"2005","unstructured":"Mu\u00f1oz-El\u00edas EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med. 2005;11:638\u201344.","journal-title":"Nat Med"},{"key":"2443_CR101","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1038\/ncomms5306","volume":"5","author":"M Nandakumar","year":"2014","unstructured":"Nandakumar M, Nathan C, Rhee KY. Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis. Nat Commun. 2014;5:4306.","journal-title":"Nat Commun"},{"key":"2443_CR102","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13578-023-00992-x","volume":"13","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Park EJ, Lee SH, Silwal P, Kim JK, Yang JS, Whang J, Jang J, Kim JM, Jo EK. Dimethyl itaconate is effective in host-directed antimicrobial responses against mycobacterial infections through multifaceted innate immune pathways. Cell Biosci. 2023;13:49.","journal-title":"Cell Biosci"},{"key":"2443_CR103","doi-asserted-by":"publisher","first-page":"18173","DOI":"10.1038\/s41598-021-97352-x","volume":"11","author":"X Zhu","year":"2021","unstructured":"Zhu X, Guo Y, Liu Z, Yang J, Tang H, Wang Y. Itaconic acid exerts anti-inflammatory and antibacterial effects via promoting pentose phosphate pathway to produce ROS. Sci Rep. 2021;11:18173.","journal-title":"Sci Rep"},{"key":"2443_CR104","doi-asserted-by":"crossref","unstructured":"Hoffmann E, Machelart A, Belhaouane I, Deboosere N, Pauwels AM, Saint-Andr\u00e9 JP, Song OR, Jouny S, Poncet A, Marion S, et al. IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection. 2019; 761551.","DOI":"10.1101\/761551"},{"key":"2443_CR105","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1084\/jem.20180118","volume":"215","author":"S Nair","year":"2018","unstructured":"Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, Boon ACM, Schwarzkopf EA, Bradstreet TR, Edelson BT, et al. Irg1 expression in myeloid cells prevents immunopathology during M. tuberculosis infection. J Exp Med. 2018;215:1035\u201345.","journal-title":"J Exp Med"},{"key":"2443_CR106","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","volume":"39","author":"CH Serezani","year":"2008","unstructured":"Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39:127\u201332.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2443_CR107","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature08123","volume":"460","author":"N Agarwal","year":"2009","unstructured":"Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature. 2009;460:98\u2013102.","journal-title":"Nature"},{"key":"2443_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002262","volume":"7","author":"S Subbian","year":"2011","unstructured":"Subbian S, Tsenova L, O\u2019Brien P, Yang G, Koo MS, Peixoto B, Fallows D, Dartois V, Muller G, Kaplan G. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 2011;7: e1002262.","journal-title":"PLoS Pathog"},{"key":"2443_CR109","doi-asserted-by":"publisher","first-page":"7888","DOI":"10.1128\/AAC.02145-15","volume":"59","author":"MC Maiga","year":"2015","unstructured":"Maiga MC, Ahidjo BA, Maiga M, Bishai WR. Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015;59:7888\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"2443_CR110","doi-asserted-by":"publisher","first-page":"e0127422","DOI":"10.1128\/mbio.01274-22","volume":"13","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Qiu Y, Kurland IJ, Drlica K, Subbian S, Tyagi S, Shi L. Glutamine is required for M1-like polarization of macrophages in response to Mycobacterium tuberculosis infection. MBio. 2022;13:e0127422.","journal-title":"MBio"},{"key":"2443_CR111","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1016\/j.celrep.2019.11.037","volume":"29","author":"K Borah","year":"2019","unstructured":"Borah K, Bey\u00df M, Theorell A, Wu H, Basu P, Mendum TA, N\u04e7h K, Beste DJV, McFadden J. Intracellular Mycobacterium tuberculosis exploits multiple host nitrogen sources during growth in human macrophages. Cell Rep. 2019;29:3580-3591.e3584.","journal-title":"Cell Rep"},{"key":"2443_CR112","doi-asserted-by":"publisher","first-page":"33162","DOI":"10.1038\/srep33162","volume":"6","author":"H Polena","year":"2016","unstructured":"Polena H, Boudou F, Tilleul S, Dubois-Colas N, Lecointe C, Rakotosamimanana N, Pelizzola M, Andriamandimby SF, Raharimanga V, Charles P, et al. Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination. Sci Rep. 2016;6:33162.","journal-title":"Sci Rep"},{"key":"2443_CR113","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature13967","volume":"517","author":"SH Oehlers","year":"2015","unstructured":"Oehlers SH, Cronan MR, Scott NR, Thomas MI, Okuda KS, Walton EM, Beerman RW, Crosier PS, Tobin DM. Interception of host angiogenic signalling limits mycobacterial growth. Nature. 2015;517:612\u20135.","journal-title":"Nature"},{"key":"2443_CR114","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.celrep.2019.04.072","volume":"27","author":"JS Harding","year":"2019","unstructured":"Harding JS, Herbath M, Chen Y, Rayasam A, Ritter A, Csoka B, Hasko G, Michael IP, Fabry Z, Nagy A, et al. VEGF-A from granuloma macrophages regulates granulomatous inflammation by a non-angiogenic pathway during mycobacterial infection. Cell Rep. 2019;27:2119-2131.e2116.","journal-title":"Cell Rep"},{"key":"2443_CR115","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1002\/1878-0261.13261","volume":"16","author":"S Drapela","year":"2022","unstructured":"Drapela S, Ilter D, Gomes AP. Metabolic reprogramming: a bridge between aging and tumorigenesis. Mol Oncol. 2022;16:3295\u2013318.","journal-title":"Mol Oncol"},{"key":"2443_CR116","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4161\/auto.28072","volume":"10","author":"CS Yang","year":"2014","unstructured":"Yang CS, Kim JJ, Lee HM, Jin HS, Lee SH, Park JH, Kim SJ, Kim JM, Han YM, Lee MS, et al. The AMPK-PPARGC1A pathway is required for antimicrobial host defense through activation of autophagy. Autophagy. 2014;10:785\u2013802.","journal-title":"Autophagy"},{"key":"2443_CR117","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molcel.2019.12.028","volume":"77","author":"J Jia","year":"2020","unstructured":"Jia J, Bissa B, Brecht L, Allers L, Choi SW, Gu Y, Zbinden M, Burge MR, Timmins G, Hallows K, et al. AMPK, a regulator of metabolism and autophagy, is activated by lysosomal damage via a novel galectin-directed ubiquitin signal transduction system. Mol Cell. 2020;77:951-969.e959.","journal-title":"Mol Cell"},{"key":"2443_CR118","doi-asserted-by":"publisher","first-page":"263ra159","DOI":"10.1126\/scitranslmed.3009885","volume":"6","author":"A Singhal","year":"2014","unstructured":"Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, Tsenova L, Kurepina N, Chen J, Zolezzi F, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6:263ra159.","journal-title":"Sci Transl Med"},{"key":"2443_CR119","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chest.2017.11.040","volume":"153","author":"SW Pan","year":"2018","unstructured":"Pan SW, Yen YF, Kou YR, Chuang PH, Su VY, Feng JY, Chan YJ, Su WJ. The risk of TB in patients with type 2 diabetes initiating metformin vs sulfonylurea treatment. Chest. 2018;153:1347\u201357.","journal-title":"Chest"},{"key":"2443_CR120","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1186\/s12879-019-4548-4","volume":"19","author":"X Yu","year":"2019","unstructured":"Yu X, Li L, Xia L, Feng X, Chen F, Cao S, Wei X. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review. BMC Infect Dis. 2019;19:859.","journal-title":"BMC Infect Dis"},{"key":"2443_CR121","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/cid\/cix819","volume":"66","author":"NR Degner","year":"2018","unstructured":"Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment. Clin Infect Dis. 2018;66:198\u2013205.","journal-title":"Clin Infect Dis"},{"key":"2443_CR122","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10096-018-3242-6","volume":"37","author":"Y Ma","year":"2018","unstructured":"Ma Y, Pang Y, Shu W, Liu YH, Ge QP, Du J, Li L, Gao WW. Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up. Eur J Clin Microbiol Infect Dis. 2018;37:1259\u201363.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2443_CR123","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/cid\/ciab964","volume":"75","author":"C Padmapriydarsini","year":"2022","unstructured":"Padmapriydarsini C, Mamulwar M, Mohan A, Shanmugam P, Gomathy NS, Mane A, Singh UB, Pavankumar N, Kadam A, Kumar H, et al. Randomized trial of metformin with anti-tuberculosis drugs for early sputum conversion in adults with pulmonary tuberculosis. Clin Infect Dis. 2022;75:425\u201334.","journal-title":"Clin Infect Dis"},{"key":"2443_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003880","volume":"19","author":"SY Yu","year":"2022","unstructured":"Yu SY, Ip MS, Li X, Cheung KS, Ren QW, Wu MZ, Li HL, Wong PF, Tse HF, Yiu KH. Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: a cohort study. PLoS Med. 2022;19: e1003880.","journal-title":"PLoS Med"},{"key":"2443_CR125","first-page":"CD011509","volume":"2015","author":"S Derry","year":"2015","unstructured":"Derry S, Wiffen PJ, Moore RA. Single dose oral ibuprofen plus caffeine for acute postoperative pain in adults. Cochrane Database Syst Rev. 2015;2015:CD011509.","journal-title":"Cochrane Database Syst Rev"},{"key":"2443_CR126","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1167\/iovs.10-5455","volume":"51","author":"EL Liclican","year":"2010","unstructured":"Liclican EL, Nguyen V, Sullivan AB, Gronert K. Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis. Invest Ophthalmol Vis Sci. 2010;51:6311\u201320.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2443_CR127","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2567.2002.01403.x","volume":"106","author":"J Rangel Moreno","year":"2002","unstructured":"Rangel Moreno J, Estrada Garc\u00eda I, De La Luz Garc\u00eda Hern\u00e1ndez M, Aguilar Leon D, Marquez R, Hern\u00e1ndez Pando R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology. 2002;106:257\u201366.","journal-title":"Immunology"},{"key":"2443_CR128","doi-asserted-by":"publisher","first-page":"13559","DOI":"10.1038\/s41598-021-92667-1","volume":"11","author":"JM Pellegrini","year":"2021","unstructured":"Pellegrini JM, Martin C, Morelli MP, Schander JA, Tateosian NL, Amiano NO, Rolandelli A, Palmero DJ, Levi A, Ciallella L, et al. PGE2 displays immunosuppressive effects during human active tuberculosis. Sci Rep. 2021;11:13559.","journal-title":"Sci Rep"},{"key":"2443_CR129","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13489","volume":"511","author":"KD Mayer-Barber","year":"2014","unstructured":"Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014;511:99\u2013103.","journal-title":"Nature"},{"key":"2443_CR130","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s42003-019-0530-3","volume":"2","author":"R Mortensen","year":"2019","unstructured":"Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P. Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice. Commun Biol. 2019;2:288.","journal-title":"Commun Biol"},{"key":"2443_CR131","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1111\/bcp.15281","volume":"88","author":"C Abdel Shaheed","year":"2022","unstructured":"Abdel Shaheed C, Beardsley J, Day RO, McLachlan AJ. Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: mechanisms and relevance to infection. Br J Clin Pharmacol. 2022;88:3114\u201331.","journal-title":"Br J Clin Pharmacol"},{"key":"2443_CR132","doi-asserted-by":"publisher","first-page":"04015","DOI":"10.7189\/jogh.12.04015","volume":"12","author":"L Tamara","year":"2022","unstructured":"Tamara L, Kartasasmita CB, Alam A, Gurnida DA. Effects of Vitamin D supplementation on resolution of fever and cough in children with pulmonary tuberculosis: a randomized double-blind controlled trial in Indonesia. J Glob Health. 2022;12:04015.","journal-title":"J Glob Health"},{"key":"2443_CR133","doi-asserted-by":"crossref","unstructured":"Miow QH, Vallejo AF, Wang Y, Hong JM, Bai C, Teo FS, Wang AD, Loh HR, Tan TZ, Ding Y, et al. Doxycycline host-directed therapy in human pulmonary tuberculosis. J Clin Invest. 2021; 131.","DOI":"10.1172\/JCI141895"},{"key":"2443_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"A Mily","year":"2015","unstructured":"Mily A, Rekha RS, Kamal SM, Arifuzzaman AS, Rahim Z, Khan L, Haq MA, Zaman K, Bergman P, Brighenti S, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS ONE. 2015;10: e0138340.","journal-title":"PLoS ONE"},{"key":"2443_CR135","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/joim.12767","volume":"284","author":"A Bekele","year":"2018","unstructured":"Bekele A, Gebreselassie N, Ashenafi S, Kassa E, Aseffa G, Amogne W, Getachew M, Aseffa A, Worku A, Raqib R, et al. Daily adjunctive therapy with vitamin D(3) and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. J Intern Med. 2018;284:292\u2013306.","journal-title":"J Intern Med"},{"key":"2443_CR136","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41420-022-00935-4","volume":"8","author":"C Xiang","year":"2022","unstructured":"Xiang C, Yan HC. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma. Cell Death Discov. 2022;8:130.","journal-title":"Cell Death Discov"},{"key":"2443_CR137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006974","volume":"14","author":"Y Xu","year":"2018","unstructured":"Xu Y, Wang L, Zimmerman MD, Chen KY, Huang L, Fu DJ, Kaya F, Rakhilin N, Nazarova EV, Bu P, et al. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathog. 2018;14: e1006974.","journal-title":"PLoS Pathog"},{"key":"2443_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197474","volume":"13","author":"AA Ordonez","year":"2018","unstructured":"Ordonez AA, Pokkali S, Kim S, Carr B, Klunk MH, Tong L, Saini V, Chang YS, McKevitt M, Smith V, et al. Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas. PLoS ONE. 2018;13: e0197474.","journal-title":"PLoS ONE"},{"key":"2443_CR139","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/infdis\/jiy373","volume":"219","author":"AA Ordonez","year":"2019","unstructured":"Ordonez AA, Pokkali S, Sanchez-Bautista J, Klunk MH, Urbanowski ME, K\u00fcbler A, Bishai WR, Elkington PT, Jain SK. Matrix metalloproteinase inhibition in a murine model of cavitary tuberculosis paradoxically worsens pathology. J Infect Dis. 2019;219:633\u20136.","journal-title":"J Infect Dis"},{"key":"2443_CR140","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/21505594.2020.1809961","volume":"11","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Lee SH, Jeon SM, Silwal P, Seo JY, Hanh BTB, Park JW, Whang J, Lee MJ, Heo JY, et al. Sirtuin 3 is essential for host defense against Mycobacterium abscessus infection through regulation of mitochondrial homeostasis. Virulence. 2020;11:1225\u201339.","journal-title":"Virulence"},{"key":"2443_CR141","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55415","volume":"9","author":"A Bhaskar","year":"2020","unstructured":"Bhaskar A, Kumar S, Khan MZ, Singh A, Dwivedi VP, Nandicoori VK. Host sirtuin 2 as an immunotherapeutic target against tuberculosis. Elife. 2020;9: e55415.","journal-title":"Elife"},{"key":"2443_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779235","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Liu Y, Zhou X, Ou M, Xiao G, Li F, Wang Z, Wang Z, Liu L, Zhang G. Sirtuin 7 regulates nitric oxide production and apoptosis to promote mycobacterial clearance in macrophages. Front Immunol. 2021;12: 779235.","journal-title":"Front Immunol"},{"key":"2443_CR143","first-page":"569","volume":"6","author":"LM Fu","year":"2002","unstructured":"Fu LM, Fu-Liu CS. Thalidomide and tuberculosis. Int J Tuberc Lung Dis. 2002;6:569\u201372.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2443_CR144","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1086\/515327","volume":"177","author":"L Tsenova","year":"1998","unstructured":"Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis. 1998;177:1563\u201372.","journal-title":"J Infect Dis"},{"key":"2443_CR145","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/15548627.2015.1091140","volume":"11","author":"V Chandra","year":"2015","unstructured":"Chandra V, Bhagyaraj E, Nanduri R, Ahuja N, Gupta P. NR1D1 ameliorates Mycobacterium tuberculosis clearance through regulation of autophagy. Autophagy. 2015;11:1987\u201397.","journal-title":"Autophagy"},{"key":"2443_CR146","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/cells9030648","volume":"9","author":"YS Kim","year":"2020","unstructured":"Kim YS, Kim JK, Hanh BTB, Kim SY, Kim HJ, Kim YJ, Jeon SM, Park CR, Oh GT, Park JW, et al. The peroxisome proliferator-activated receptor \u03b1- agonist gemfibrozil promotes defense against mycobacterium abscessus infections. Cells. 2020;9:648.","journal-title":"Cells"},{"key":"2443_CR147","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.immuni.2015.07.003","volume":"43","author":"JM Yuk","year":"2015","unstructured":"Yuk JM, Kim TS, Kim SY, Lee HM, Han J, Dufour CR, Kim JK, Jin HS, Yang CS, Park KS, et al. Orphan nuclear receptor ERR\u03b1 controls macrophage metabolic signaling and A20 expression to negatively regulate TLR-induced inflammation. Immunity. 2015;43:80\u201391.","journal-title":"Immunity"},{"key":"2443_CR148","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8\u201327.","journal-title":"Immunol Rev"},{"key":"2443_CR149","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1515\/bmc-2021-0003","volume":"12","author":"K To","year":"2021","unstructured":"To K, Cao R, Yegiazaryan A, Owens J, Sasaninia K, Vaughn C, Singh M, Truong E, Sathananthan A, Venketaraman V. The effects of oral liposomal glutathione and in vitro everolimus in altering the immune responses against Mycobacterium bovis BCG strain in individuals with type 2 diabetes. Biomol Concepts. 2021;12:16\u201326.","journal-title":"Biomol Concepts"},{"key":"2443_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005007","volume":"11","author":"AK Coussens","year":"2015","unstructured":"Coussens AK, Wilkinson RJ, Martineau AR. Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3. PLoS Pathog. 2015;11: e1005007.","journal-title":"PLoS Pathog"},{"key":"2443_CR151","doi-asserted-by":"publisher","first-page":"15449","DOI":"10.1073\/pnas.1200072109","volume":"109","author":"AK Coussens","year":"2012","unstructured":"Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A. 2012;109:15449\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2443_CR152","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/jac\/dkw014","volume":"71","author":"NK Dutta","year":"2016","unstructured":"Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, Gennaro ML, Karakousis PC. Statin adjunctive therapy shortens the duration of TB treatment in mice. J Antimicrob Chemother. 2016;71:1570\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"2443_CR153","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","volume":"18","author":"F Atzeni","year":"2022","unstructured":"Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022;18:233\u201344.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02443-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:02:13Z","timestamp":1744369333000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02443-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02443-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}